Neurodegenerative Disease Therapeutics Industry Future And Journey Of Decoding The Cure

  

 

Neurodegenerative Disease Therapeutics Industry Data Book Covers Parkinson’s Disease Treatment and Alzheimer's Therapeutics Market. The global neurodegenerative disease industry combine to account for USD 8.33 billion revenue in 2021, which is expected to reach USD 28.15 billion by 2030, growing at a cumulative rate of 15.6% over the forecast period.

 

Global neurodegenerative disease therapeutics industry data book is a collection of market sizing & forecasts insights, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, macro-environmental analyses studies. Within the purview of the database, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research.The following data points will be included in the final product offering in two reports and one sector report overview.

 

Access the Global Neurodegenerative Disease Therapeutics Industry Data Book, 2023 to 2030, Compiled Report By Grand View Research

 

 

Parkinson’s Disease Treatment Market Insights

The global Parkinson’s disease treatment market size was valued at USD 4.28 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 12.1% from 2022 to 2030.

 

Parkinson’s Disease Treatment Market Report Highlights

• By drug class, the Carbidopa-Levodopa segment held the largest revenue share in 2021 due to the high prevalence of PD and easy drug availability for the disease treatment
• The retail pharmacy distribution channel segment dominated the global industry in 2021
• This is due to the easy availability of PD drugs in well-established retail pharmacy chains including Walgreens and Walmart
• Asia Pacific is expected to be the fastest-growing region during the forecast period due to the entry of new products into the market
• In June 2020, Ono Pharmaceutical Co., Ltd. received manufacturing and marketing approval for Ongentys to treat patients with PD in Japan

 

Alzheimer's Therapeutics Market Report Highlights

• By product, the cholinesterase inhibitors segment held the largest revenue share in 2022 as it is the current standard of care. In March 2022, the U.S. FDA approved the cholinesterase inhibitor Adlarity (donepezil hydrochloride) developed by Corium Inc. for the treatment of patients with AD
• Pipeline drugs are anticipated to witness the fastest growth over the forecast period due to the presence of a strong product pipeline and their expected launch during the forecast period. Biogen’s product lecanemab (BAN2401), an anti-amyloid beta protofibril antibody for treating AD, is currently in phase 3 clinical trials
• The hospital pharmacy end-user segment dominated the market in 2022 owing to the high hospitalization rate. According to Alzheimer’s Association report 2022, approximately 32% of total Medicare beneficiaries with Alzheimer’s have at least one hospital discharge annually

 

Order your copy of the Free Sample of “Neurodegenerative Disease Therapeutics Industry Data Book - Parkinson’s Disease Treatment and Alzheimer's Therapeutics Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research 

 

 

Neurodegenerative Disease Therapeutics Industry Data Book Competitive Landscape

Competitive rivalry in this market is likely to be high due to increasing number of mergers, acquisitions, and partnerships undertaken by major players globally. Many established and clinical-stage pharmaceutical companies are involved in the development of novel therapies & drugs to target people with unmet clinical needs.

 

Key players operating in the Neurodegenerative Disease Therapeutics industry are –

• Eisai Co., Ltd.
• AbbVie Inc. (Allergan Plc.)
• Merck & Co., Inc.
• Adamas Pharmaceuticals, Inc.
• Novartis AG,H. Lundbeck A/S
• Cerevel Therapeutics
• Biogen
• Daiichi Sankyo Company, Limited
• F. Hoffmann La Roche Ltd.
• TauRx Pharmaceuticals Ltd.
• Johnson & Johnson Services, Inc.
• AC Immune
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc. (GSK). 

Healthcare 3D Printing Industry Promises Of Biofabrication For A Healthier Tomorrow

 

 

Global healthcare 3D printing industry data book is a collection of market sizing information & forecasts, regulatory data, reimbursement structure, competitive benchmarking analyses, macro-environmental analyses, and regulatory & technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research. 

 

The healthcare 3D printing industry was valued at USD 9.4 billion in 2022 and is estimated to witness a CAGR of 17.0% over the forecast period. 

 

Healthcare Additive Manufacturing Market Growth & Trends

 

The global healthcare additive manufacturing market size was estimated at USD 7.4 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 18.1% from 2023 to 2030. The growing demand for customized medical and dental additives, including personalized implants, medical models, orthodontic appliances, splints, dental models, and others, is expected to drive the market's growth over the forecast period. 

 

In healthcare, the requirement of every patient is unique, which has led to the high potential of additive manufacturing for customized and personalized medical applications. Moreover, the rising initiatives by the organization and the government to support small and medium-sized companies are expected to propel growth. For instance, in May 2022, U.S. President Joe Biden launched Additive Manufacturing Forward by joining five leading manufacturers in the U.S. to aid small-sized suppliers based in the U.S. to increase the utilization of additive manufacturing.

 

3D Bioprinting Market Growth & Trends

 

The global 3D bioprinting market size was valued at USD 2.0 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 12.48% from 2023 to 2030. The market is driven by the global organ donation shortage and utilization and demand for 3D Bioprinting to reduce animal testing of chemical, cosmetic, and pharmaceutical products. According to the organdonor.gov by the Health Resources and Services Administration, as of January 2023, around 104,234 individuals in the U.S. were waiting for organ transplantation list in the U.S. and around 88,901 individuals among them were waiting for kidney transplantation. Moreover, 3D Bioprinting is increasingly used as an alternative to animal experimentation in biomedical research. For instance, in February 2022, Bioprinting by light-sheet lithography: engineering of complex tissues with high resolution at a high-speed project (BRIGHTER Project) collaborated with the Institute of Bioengineering of Catalonia (IBEC) in the development of technology for the production of functional human tissues to replace animal testing.

 

3D Printed Drugs Market Growth & Trends 

 

The global 3D printed drugs market size was valued at USD 86.2 million in 2022 and is expected to expand at a CAGR of 14.78% from 2023 to 2030. The rising demand for personalized medicine and the growing adoption of R&D activities for the adoption of 3D printing in drug manufacturing is expected to drive the market growth during the forecast period. 3D printed drugs can manufacture tailored dosages and significantly reduce the cost of the products; hence, many pharmaceutical corporations are adopting this technology to innovate the products. For instance, in February 2020, Merck collaborated with AMCM to develop and produce GMP tablet formulation by 3D printing technology for clinical trials and commercial manufacturing services.

 

Order your copy of Free Sample of “Healthcare 3D Printing Industry Data Book - Healthcare Additive Manufacturing, 3D Bioprinting and 3D Printed Drugs Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

 

Competitive Landscape

 

Key players operating in the Healthcare 3D Printing Industry are –

• 3D Systems, Inc.
• EnvisionTEC
• Stratasys Ltd.
• Allevi, Inc.
• GE Healthcare
• Nanoscribe GmbH
• Materialise N.V.
• Cyfuse Biomedical
• RegenHU
• Renishaw

Female Infertility Industry Helps In Cracking The Fertile Code: Innovation And Advancements

 

 

Global female infertility industry data book is a collection of market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking analyses, macro-environmental analyses, and regulatory & technological framework studies. Within the purview of the database, such information is systematically analyzed and provided in the form of outlook reports and summary presentations on individual areas of research along with a digital healthcare statistics e-book.

 

 

The global female infertility market size was valued at USD 25.7 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5.97% from 2023 to 2030.

 

In Vitro Fertilization Market Growth & Trends

 

The global In-Vitro Fertilization (IVF) market size was valued at USD 23.6 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 5.72% from 2023 to 2030. This can be attributed to higher success rates and the introduction of advanced technologies, such as Percutaneous Epidydimal Sperm Aspiration and Testicular Sperm Extraction (PESA & TESE), three-parent IVF, mini-IVF, and others. Moreover, an increase in government funding for IVF is expected to boost segment growth over the forecast period. For instance, in May 2022, in Australia, under NSW Government 2022-23 budget, women in New South Wales opting for IVF will be provided with a USD 2,000 cash rebate to reduce the costs of the treatment for patients.

 

Fertility clinics and hospitals are key end-use segments analyzed in this study. Fertility clinics accounted for the maximum share of the market in 2022 and will continue to dominate the market during the forecast period, being the most preferred setting for physicians and surgeons. Licensed fertility clinics offer counseling to couples facing problems in conceiving. Based on the severity of their problems, doctors and specialists plan their IVF treatment. The IVF treatments offered by hospitals are generally more expensive than fertility clinics. IVF treatments require highly skilled physicians and staff. Hence, employing dedicated staff for IVF in hospitals is a less preferable approach. 

 

Artificial Insemination Market Growth & Trends

 

The global artificial insemination market is valued at USD 2.1 billion as of 2022 and is expected to expand at a CAGR of 8.58% for the forecast period 2023-2030. This can be majorly attributed to the demand for minor fertility treatments and lower costs of treatment compared to IVF. Intrauterine insemination is the preferable treatment among all types of artificial insemination procedures. The intrauterine mode of insemination involves placing the sperm sample directly in the uterus and yields higher pregnancy rates. It is a non-invasive technique and is preferred by most of the infertile couples.

 

The market’s growth is driven by the lower cost of treatment, which is more suitable for minor fertility conditions and same-sex couples or single women. As per Human Fertilization and Embryology Authority (HFEA), the success rate of artificial insemination per cycle ranges from 15.8% for women under 35 to 11% for women aged 35 to 39, and 4.7% for women aged 40 to 42. Over the first six cycles, more than half of the women who had IUI reported pregnancy.

 

IUI is preferred over other methods as it is noninvasive, affordable, can be easily performed, there are minimum risks involved, and is easy to train. The pregnancy rate by IUI is higher than that by other modes of insemination. 

 

Order your copy of Free Sample of “Female Infertility Industry Data Book - In Vitro Fertilization (IVF) and Artificial Insemination Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research 

 

Competitive Landscape

Key players operating in the Female Infertility Industry are –

• Ferring B.V.
• Vitrolife AB
• CooperSurgical, Inc.
• Cosmos Biomedical Ltd.
• Merck KGaA
• Cryolab Ltd.
• FUJIFILM Irvine Scientific
• Bloom IVF Centre
• Microm UK Ltd.
• OvaScience
• Irvine Scientific
• Progyny, Inc.
• EMD Serono Inc.
• Thermo Fisher Scientific Inc.
• Boston IVF

Cancer Diagnostics Industry | Cutting-Edge Technologies Revolution

Global cancer diagnostics industry data book is a collection of market sizing & forecasts insights, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analyses studies. Within the purview of the database, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research. 

The global cancer diagnostics market is combined to account for USD 45.66 billion revenue in 2022, which is expected to reach USD 89.02 billion by 2030, growing at a cumulative rate of 5.97% over the forecast period. 

 

Breast Cancer Diagnostics Market Growth & Trends

 

The global breast cancer diagnostics market size was valued at USD 16.26 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 7.24% from 2023 to 2030. The growth can be attributed to the increasing prevalence of cancer and rising government initiatives to increase the screening and diagnostic rate. Increased R&D in advanced breast cancer screening tools is anticipated to boost the market significantly.

 

The UK Research and Innovation, in February 2020, received over USD 1300 million from the Engineering and Physical Sciences Research Council to develop a novel Raman spectroscopy platform for noninvasive and in vivo diagnostics of breast cancer. The approach would allow immediate and accurate diagnosis in conjunction with mammography by improving surveillance or screening techniques that would lead to better treatment outcomes & early diagnosis. Moreover, increased product launch is anticipated to boost market growth over the forecast period. In February 2023, NGeneBio launched an NGS-based breast cancer diagnostics test in Thailand. Moreover, in October 2022, NAMIDA LAB announced plans to launch Auria, an at-home breast assessment test. Thus, an increase in such initiatives undertaken by market players is expected to propel the adoption of breast cancer diagnostic tests in the near future. 

 

Cervical Cancer Diagnostic Market Growth & Trends

 

The global cervical cancer diagnostic market was valued at USD 4.55 billion in 2022 and is projected to grow at a CAGR of 5.65% over the forecast period. Women between the age group of 20 and 60 years are usually more prone to this ailment, which is expected to increase cervical cancer screening and diagnostics procedures. 

 

New approvals and product launches due to high investments by market players are likely to boost the market. In November 2021, Hologic, Inc. announced the Genius Digital Diagnostics System launch and made it commercially available in Europe. This innovative NGS system combines advanced volumetric imaging technology with AI. In March 2023, Roche entered into a partnership with CAPED for the launch of a cervical cancer screening program in India to enhance and promote cancer care globally. The increase in the use of novel products by major market players for various cervical screening programs is expected to boost the market during the forecast period. 

Lung Cancer Diagnostics Market Growth & Trends

 

The global lung cancer diagnostics market size was estimated at USD 10.82 billion in 2022. Technological advancements in tumor diagnosis contribute to market growth. An increase in the availability of various technologically advanced products for cancer diagnostics is a major factor anticipated to fuel the market during the forecast period. Companies such as Oncocyte offer DetermaDx, a multigene assay that can help measure gene expression in circulating blood cells to identify lung nodules, avoiding invasive biopsy procedures. In January 2020, Oncocyte acquired Insight Genetics to develop a PCR-based Immune Modulation (IM) Score Test. The test is expected to help measure the state of the immune system during a biopsy procedure and identify patient response to PD-1/PD-L1 immunotherapies. 

 

Similarly, in March 2023, Roche Diagnostics Korea announced the launch of uPath PD-L1, an automated AI tool used to detect PD-L1 biomarkers in NSCLC patients. Moreover, in June 2022, Biocartis received a CE marking for Idylla GeneFusion Panel, which is an IVD-based lung cancer screening solution for laboratories. Such innovative product launches are anticipated to drive the market growth over the forecast period. 

 

Order your copy of Free Sample of “Cancer Diagnostics Industry Data Book - Breast Cancer Diagnostic, Cervical Cancer Diagnostic, Lung Cancer Diagnostic, Liver Cancer Diagnostic, Pancreatic Cancer Diagnostic and Ovarian Cancer Diagnostic Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

Pancreatic Cancer Diagnostic Market Growth & Trends

 

The global pancreatic cancer diagnostic market size was valued at USD 3.63 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.43% from 2023 to 2030. Several key factors are driving the global market for pancreatic cancer diagnostics. Factors include the increasing prevalence of pancreatic cancer and a growing awareness of the importance of early disease diagnosis. Additionally, advancements in technology have led to improved accuracy and sensitivity of diagnostic tests and the evolution of molecular diagnostics and biomarker tests for detecting malignancies. These factors collectively propel the market demand for pancreatic cancer diagnostic solutions.

 

Early diagnosis plays a crucial role in achieving positive treatment outcomes for pancreatic cancer. Consequently, market players and healthcare organizations are actively raising funds, conducting awareness programs, and initiating research initiatives to promote routine checkups and screenings. For example, in August 2022, the Pancreatic Cancer Action Network (PanCAN) awarded USD 10.5 million in grants to support 16 new research and development projects focused on early detection and improved treatment options for pancreatic cancer.

Ovarian Cancer Diagnostics Market Growth & Trends

 

The global ovarian cancer diagnostics market size was estimated at USD 4.41 billion in 2022 and is expected to grow at a CAGR of 4.93% during the forecast period. An increase in the number of R&D activities to develop novel diagnostic tests for ovarian cancer is expected to propel the market. For instance, scientists from the University of Gothenburg and Uppsala University developed a blood test that can provide precise diagnostics for ovarian cancer, which could eliminate the requirement for exploratory surgery. This novel test can decrease the requirement for surgery and aid in the early detection and treatment of affected women. 

 

In February 2020, a study conducted by two hospitals in Australia focused on women with advanced ovarian cancer. It used an immune marker for inflammation and other cancer markers to detect epithelial ovarian cancer. The test can be used by women staying in remote areas or disadvantaged communities, where there are limited resources for diagnosis of ovarian cancer, thus improving their chances of survival. The blood test is used to measure a body’s immune response to enhance the diagnosis of ovarian cancer. 

Liver Cancer Diagnostics Market Growth & Trends

 

The global liver cancer diagnostics market size was valued at USD 5.99 billion in 2022 and is anticipated to expand at a compound annual growth rate (CAGR) of 5.96% by 2030. Liver cancer is a significant contributor to cancer-related deaths worldwide. According to the American Cancer Society, the incidence of liver cancer has tripled in the last three decades, with death rates also doubling. In 2022, it was approximately 41,260 new cases of liver cancer will be diagnosed in the U.S., resulting in approximately 30,520 deaths. The global prevalence of liver cancer, combined with the continuous exposure of the population to risk factors, will drive the rapid growth of the screening and diagnosis market. 

 

Various risk factors contribute to the development of liver cancer, including lifestyle choices such as smoking, alcohol consumption, and tobacco chewing, as well as underlying conditions like chronic viral hepatitis (hepatitis B virus or hepatitis C virus), cirrhosis, type 2 diabetes, and obesity. The presence of one or more risk factors increases the likelihood of liver cancer. Accurate early detection, diagnosis, and staging are crucial for improving survival rates. 

  

Key players operating in the Cancer Diagnostics Industry are –

• GE Healthcare
• Abbott
• F. Hoffmann-La Roche Ltd.,
• QIAGEN
• BD
• Siemens Healthcare GmbH,
• Thermo Fisher Scientific; Inc.
• Hologic, Inc.
• Koninklijke Philips N.V. (Philips)
• IIumina, inc.

Livestock Artificial Insemination Industry | Breeding Brilliance and Cutting Edge of Livestock AI

 

 

Global livestock artificial insemination industry data book is a collection of market sizing information & forecasts, regulatory data, competitive benchmarking analyses, macro-environmental analyses, and technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.

 

The global livestock artificial insemination market size was estimated at USD 6.45 billion in 2022 and is anticipated to increase at a CAGR of 6.30% from 2023 to 2030.

 

Bovine Artificial Insemination Market Growth & Trends

 

The global bovine artificial insemination market size was valued USD 2.84 billion in 2022, registering a CAGR of 6.17% over the forecast period, according to a new report by Grand View Research, Inc. Some of the key factors driving the growth include the increasing uptake of artificial insemination solutions, technological advancements, demand for meat, milk, and dairy products, and supportive initiatives by the private & public sectors. In 2022, for instance, ABS Global - the bovine genetics division of Genus plc, reported a revenue of USD 340.64 million with an estimated 3% increase in volumes of bovine semen and embryo. The company also reported an 18% increase in volumes of sexed semen for its Sexcel and IntelliGen portfolios.

 

Equine Artificial Insemination Market Growth & Trends

The global equine artificial insemination market size was valued USD 0.64 billion in 2022, expanding at a CAGR of 5.80% from 2023 to 2030, according to a new report by Grand View Research, Inc. The rising adoption of artificial insemination (AI) in horses, awareness about the benefits of AI, and demand to increase animal productivity are some of the key factors propelling the market growth. For instance, AI eliminates the risks associated with handling aggressive stallions, reducing the chances of injuries to both horses and handlers. It also enables breeders to manage and monitor mare fertility more effectively. By controlling the timing of insemination and monitoring the mare's reproductive cycle, breeders can optimize the chances of successful conception. Furthermore, AI facilitates breeders to access stallions located in different parts of the world without the need for transporting the animals physically. This opens up opportunities for international and long-distance breeding, facilitating the exchange of genetic material across borders. These factors are expected to fuel the market growth in the coming years.

 

Swine Artificial Insemination Market Growth & Trends

The global swine artificial insemination market size was valued USD 1.91 billion in 2022, expanding at a CAGR of 6.67% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is characterized by initiatives by key companies, demand for sustainable food production, consumption of pork, and growing uptake of artificial insemination in swine. Semen Cardona S.L. one of the key players in the market reported that the company was exploring opportunities in emerging markets such as Mexico, Colombia, and the Philippines. In the year 2022 alone, the company distributed more than 0.7 million semen doses in Mexico with scope for further growth. Similar initiatives are propelling market growth. Moreover, the increasing consumption of pork is anticipated to contribute to the demand for AI services to ensure production safety, sustainability, and efficiency. Consumption of pork meat is expected to increase from 112.58 megatons to 127.27 megatons from 2022 to 2029 according to estimates by OECD. 

 

Order your copy of Free Sample of “Livestock Artificial Insemination Industry Data Book - Bovine, Equine, Swine, Ovine & Caprine Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

 

Ovine And Caprine Artificial Insemination Market Growth & Trends

The global ovine and caprine artificial insemination market size was valued USD 1.06 billion in 2022, expanding at 6.25% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. Drivers contributing to the market growth include increasing access to buck (a male goat) and ram (a male sheep) semen, improved reproductive efficiency by adopting artificial insemination, and demand for genetic improvement in the sheep and goat industries. Artificial insemination allows farmers and breeders to access high-quality genetics from superior male animals. By using AI, they can introduce desired traits such as improved meat quality, milk production, disease resistance, and reproductive performance into their herds or flocks. As technology continues to advance and demand for quality genetics grows, the market is expected to expand further during the forecast period. 

Key players operating in the Livestock Artificial Insemination Industry are –

• Genus Plc
• SEMEX
• URUS Group
• STgenetics
• Munster Bovine
• Stallion AI Services
• MINITÜB GMBH
• IMV Technologies
• B&D Genetics
• SEK Genetics
• Semen Cardona S.L.
• Swine Genetics International

Diagnostic Imaging Industry Growth Hacks and Pixels with Potential

  

 

Global diagnostic imaging industry data book is a collection of market sizing information & forecasts, regulatory data, reimbursement structure, competitive benchmarking analyses, macro-environmental analyses, and regulatory & technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.

 

The global diagnotic imaging market size was valued at USD 29.47 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 4.83% from 2023 to 2030.  

 

Computed Tomography Market Growth & Trends

 

The global computed tomography market size was valued at USD 4.2 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 7.43% from 2023 to 2030. Technological advancements in CT technology, coupled with the growing prevalence of chronic disorders such as cancer, orthopedics, and cardiovascular and neurological conditions are expected to accelerate the market growth.

 

CT scan is a most important diagnostic tool, predominantly for traumatic brain injuries and lung cancer. The prevalence of these illnesses is fostering market expansion. The growing elderly population, the prevalence of chronic diseases, the change in medical care toward image-guided interventions, and technology improvements are further market drivers. Lung cancer is one of the most frequently diagnosed cancer, according to the American Cancer Society, Inc., around 238,340 residents in the U.S. are expected to get diagnosed with lung cancer, and 127,070 deaths are estimated in 2023.

 

Additionally, the organization has stated that 654,620 inhabitants have a history of lung cancer, among which about 80% of patients were of age 65 years or above as of January 2022. Incidences of lung cancer are predicted to rise by 38% to 2.89 million globally by 2030. A CT scan produces 3D images of the bones that aid in orthopedic surgery and improved diagnosis. Consequently, as the prevalence of orthopedic problems rises, so does the need for CT increases, leading to the market growth.

 

Magnetic Resonance Imaging Market Growth & Trends

 

The global magnetic resonance imaging market size was valued at USD 5.25 billion in 2022 and is expected to expand at a CAGR of 6.81% from 2023 to 2030. Magnetic Resonance Imaging (MRI) is an efficient diagnostic machine for identifying diseases related to spine lesions, tumors, and strokes impacting the area of blood vessels and the brain. The increasing prevalence of diseases is driving the market growth.

 

Moreover, Magnetic resonance imaging is a crucial technique to diagnose cancer/tumor and to plan treatment such as radiation therapy or surgery for cancer patients. Hence, the increasing burden of cancer is expected to fuel the MRI market globally. For instance; according to National Center for Health Statistics, in 2023, almost 1,958,310 new cancer cases and 609,820 cancer deaths are estimated to occur in the United States.

 

Nuclear Imaging Market Analysis And Forecast

 

The global nuclear imaging market size was estimated at USD 4.67 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 4.95% from 2023 to 2030. Factors such as changing preference from standalone devices to hybrid imaging modalities, growing focus on personalized medicinal treatments, advancements in the healthcare infrastructure, and rising prevalence of chronic diseases such as cardiac ailments & cancer are fueling the nuclear imaging market’s growth during the forecast period.

 

Rising awareness levels among physicians and clinical researchers regarding the benefits of nuclear imaging coupled with increasing application areas such as cases in oncology, and neurological diseases are the factors driving PET and SPECT market. Furthermore, the increasing geriatric population and expanding horizon of applications in SPECT and PET imaging owing to constant discovery and developments of new radiopharmaceuticals are driving the diagnostic imaging market.

 

Order your copy of Free Sample of “Diagnostic Imaging Industry Data Book - Computed Tomography, Magnetic Resonance Imaging, Nuclear Imaging, Ultrasound Device and X-ray Systems Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

 

Ultrasound Device Market Analysis And Forecast

The global ultrasound device market size was valued at USD 7.36 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 4.03% from 2023 to 2030. The rising use of ultrasound equipment for diagnostic imaging and therapy, as well as the rising prevalence of chronic and lifestyle-related illnesses are the key factors anticipated to drive the market’s growth. Additionally, technological advancements in ultrasound devices, and rising demand for minimally invasive surgeries are expected to create lucrative growth opportunities.

 

Ultrasound technology is used in various application areas such as cardiology, obstetrics/ gynecology, vascular, orthopedic, and general imaging. The rising prevalence of cardiac disorders is expected to boost the ultrasound device market globally. According to WHO, Cardiovascular diseases (CVDs) are the major cause of death globally, taking approximately 17.9 million lives each year. Additionally, as per the Centers for Disease Control & Prevention, in the United States, every year about 805,000 people have a heart attack and about 1 in 20 adults age 20 and older have Coronary Artery Disease (about 5%).

 

X-ray Systems Market Analysis And Forecast

The global x-ray systems market size was valued at USD 7.89 billion in 2022 and is anticipated to expand at a compound annual growth rate (CAGR) of 2.28% from 2023 to 2030. Rising demand for early disease diagnosis, constant technological advances, increase in product development, favorable healthcare funding, and rising government investments in developing countries are expected to fuel the market growth.

 

Additionally, the rising geriatric population and growing prevalence of orthopedic trauma due to severe accidents are some of the inevitable factors supporting the market’s growth. According to United Nations, the number of people aged 65 years or above is expected to reach 1.6 billion in 2050, accounting for more than 16% of the global population. The geriatric population is prone to develop conditions such as arthritis, osteoporosis, and bone fractures. According to the Centers for Disease Control and Prevention, around 23.7% or nearly 58.5 million inhabitants are diagnosed with arthritis. More women (23.5%) are predominantly suffering from the disease compared to men (18.1%).

Facial Rejuvenation Products Industry Latest Trends From Wrinkles to Rejuvenation

 

 

The facial rejuvenation products industry database, compiled by Grand View Research, is a collection of market sizing information & forecasts, regulatory data, reimbursement structure, competitive benchmarking analyses, macro-environmental analyses, and regulatory & technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.

 

The global facial rejuvenation products market size was valued at USD 109.03 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 6.6% from 2023 to 2030.

 

 

Facial Injectable Market Growth & Trends

 

The global facial injectable market size was estimated at USD 12.7 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 10.3% from 2023 to 2030. A growing focus on physical appearance among consumers has led to an increased demand for facial injectables in recent years. Increasing awareness regarding minimally invasive procedures due to various beauty campaigns being organized by key players in the market is also a driving factor for market growth. The ongoing COVID-19 pandemic has increased the time spent on video calls. Known as the ‘Zoom Boom’, several adults are becoming more aware of their appearance. This has increased demand for cosmetic surgeries, with Botox being one of the most popular products preferred.

 

Skin Boosters Market Growth & Trends

 

The global skin boosters market size was estimated at USD 1.03 billion in 2022 and is expected to grow at a CAGR of 9.6% from 2023 to 2030. The desire to look youthful among the millennials and the rising consumption of aesthetic procedures by both men and women, especially from emerging economies are majorly estimated to drive the market. However, the advent of the COVID-19 pandemic has hugely affected the overall non-invasive aesthetic industry. However, many aesthetic professionals believe that pandemics might most likely propel the overall growth of the aesthetic market. Many dermatology clinics have witnessed a boost in the number of future appointments and consultations for different skin treatments and this is expected to boost the market growth.

 

Facial Skincare Market Analysis And Forecast

 

The global facial skincare market size was estimated at USD 90.8 billion in 2022 and is expected to grow at a CAGR of 5.8% from 2023 to 2030. Rising awareness regarding the importance of facial products in maintaining healthy skin, enhancing skin appearance, and minimizing skin conditions is driving the industry of these products. In the past few years, facial care products have contributed to almost 70.0% share of the overall revenue in the skincare market. Manufacturers have realized the significance of these products among consumers and have shifted their focus toward facial beauty products. Manufacturers have started their brand campaigns through various social media platforms such as Facebook, Instagram, and YouTube to market their products. Key players have collaborated with different celebrities and appointed them as brand ambassadors of their products to attract more customers.

 

Order your copy of Free Sample of “Facial Rejuvenation Products Industry Data Book - Facial Injectable, Skin Boosters, Facial Skincare and Anti-Acne Cosmetics Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

 

Anti-acne Cosmetics Market Growth & Trends

 

The global anti-acne cosmetics market size was estimated at USD 4.5 billion in 2022 and is expected to grow at a CAGR of 9.1% from 2023 to 2030. The negative social stigma associated with acne and the rising consumption of cosmetics by both men and women, especially from emerging economies are majorly estimated to drive the market growth. The incidence of acne increased during the pandemic, which, in turn, accelerated the market growth. Acne is a highly prevalent skin disorder among adolescents. According to an article published by the Journal of The European Academy of Dermatology and Venereology, more than 95% of boys and nearly 85% of girls are affected by acne during their adolescence. Out of these, nearly 40% experience moderate‐to‐severe acne and nearly 50% continue to have acne in their adulthood. The high prevalence of acne, especially in the young population, is anticipated to fuel market growth.

  

Competitive Landscape

Key players operating in the Facial Rejuvenation Products Industry are –

• Ipsen
• Merz Pharma
• Suneva Medical, Inc.
• Medytox Inc.
• Sinclair Pharma
• Bloomage BioTechnology Corporation Limited
• Anika Therapeutics Inc.
• Prollenium Medical Technologies
• Galderma
• Allergan, Inc.
• Nestle Skin Health
• Zimmer Biomet
• Abbvie Inc
• SciVision Biotech Inc
• Croma-Pharma GmbH
• Revance Therapeutics Inc
• Bioplus Co. Ltd
• Bioaxis Pharmaceuticals

Clinical Laboratory Industry Diagnostics, Challenges and Opportunities

  

 

Global clinical laboratory industry data book is a collection of market sizing & forecasts insights, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, macro-environmental analyses studies. Within the purview of the database, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research.The following data points will be included in the final product offering in two reports and one sector report overview. 

 

The global clinical laboratory market combine to account for USD 321.20 billion in revenue in 2022, which is expected to reach USD 493.72 billion by 2030, growing at a cumulative rate of 5.52% over the forecast period. The combination bundle is designed to provide a holistic view of these highly dynamic market spaces.  

 

Clinical Laboratory Tests Market Growth & Trends

 

The global clinical laboratory tests market was valued at USD 103.67 billion in 2022 and is anticipated to witness growth at a rate of 9.42% over the forecast period. The market growth can be attributed to the increasing adoption of clinical laboratory tests, increasing prevalence of targeted diseases, and rising geriatric population. According to the UN data, in 2020, there were around 727 million individuals aged 65 and above globally. Moreover, the share of the global population aged 65 and above is expected to grow from 10% in 2022 to 16% in 2050. Aging is considered a great risk factor for developing chronic diseases, which is expected to fuel the demand for clinical laboratory tests over the forecast period. 

 

Growing prevalence of target diseases such as cardiovascular diseases, diabetes, and others is anticipated to fuel market growth. According to the WHO, in 2021, cardiovascular diseases are the leading cause of death globally. Around 17.9 million people die each year due to CVDs, which is about 31% of total death worldwide. The mortality rate of CVDs is higher in low and middle-income countries compared to high-income countries due to the low penetration rate of clinical tests in these regions. High unmet medical needs in developing regions are anticipated to create new opportunities for the market stakeholders. Moreover, increasing awareness among people regarding early diagnosis of diseases is anticipated to propel the market growth over the projected period.

 

Clinical Laboratory Service Market Growth & Trends

 

The global clinical laboratory service market was valued at USD 217.53 billion in 2022 and is anticipated to witness growth at a rate of 3.24% over the forecast period. Increasing burden of chronic diseases, growing demand for early diagnostic tests, and increasing research activities to develop novel diagnostic and therapeutic solutions are expected to increase the market for clinical laboratory service market. Moreover, advancements in data management and sample preparation due to the growing volume of testing are further supporting the market growth. 

 

Increasing research activities by pharmaceutical & biotechnology companies and research & academic institutes are driving the demand for clinical laboratory services to study different health conditions across the globe. As of January 2023, ClinicalTrials.gov registered 439,527 research studies, out of which, around 31% of clinical studies were registered in the U.S. Moreover, the presence of intense research activities related to genetic & proteomics, cancer, and other life-threaten diseases is expected to drive revenue generation in the coming years. Presence of several genetic and tumor tests in the development phases is further anticipated to fuel the market growth. 

 

Most research studies are being conducted in North America and Europe region. A large number of clinical studies conducted in these regions are due to favorable government policies, the presence of strong market players coupled with heavy investments done by them in R&D activities. However, research activities are expected to increase in the Asia Pacific region over in next couple of years. Increasing shift towards the APAC region, high unmet medical needs, low operational cost, and increasing contract research organizations in the region will boost the demand for clinical laboratory services in the region.

 

Order your copy of Free Sample of “Clinical Laboratory Industry Data Book - Clinical Laboratory Tests and Clinical Laboratory Service Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

 

Competitive Landscape

 

Key players operating in the Clinical Laboratory Industry are –

• Abbott
• ARUP Laboratories
• OPKO Health, Inc.
• Bioscientia Healthcare GmbH
• Charles River Laboratories
• NeoGenomics Laboratories
• Healthscope
• Labco
• Laboratory Corporation of America Holdings
• Fresenius Medical Care AG & Co. KGaA
• QIAGEN
• Quest Diagnostics Incorporated
• Siemens Healthcare GmbH
• Tulip Diagnostics (P) Ltd
• Sonic Healthcare Limited
• Merck KGaA
• Biosino Bio-Technology and Science Inc.
• Cinven
• DaVita Inc.
• SGS Société Générale de Surveillance SA
• Almac Group

The Active Pharmaceutical Ingredients and High Potency API Industry 2023-2030: Fueling the Future of Medicine

 

 

Global API and High Potency API industry databook is a collection of market sizing & forecasts insights, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, macro-environmental analyses studies. Within the purview of the database, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research.The following data points will be included in the final product offering in two reports and one sector report overview. 

 

The global active pharmaceutical ingredients market was valued at USD 209.71 billion in 2021 and is anticipated to witness growth at a rate of 5.9% over the forecast period. The global high potency API market was valued at USD 23.60 billion in 2021 and is anticipated to witness growth at a rate of 6.2% over the forecast period. 

 

Active Pharmaceutical Ingredients Market Growth & Trends

 

The global active pharmaceutical ingredients market was valued at USD 209.71 billion in 2021 and is anticipated to witness growth at a rate of 5.9% over the forecast period. The Active Pharmaceutical Ingredients market is becoming more competitive and consumer needs are becoming highly focused toward efficacy & specificity of therapeutic agent raw material. Buyers tend to purchase materials matching their requirements and negotiate the price. Thus, buyers are highly involved in the purchasing process to ensure quality of material matches their requirement.

 

High capital is required for production of APIs because the process needs extremely systematic protocols, which leads to increase in outsourcing of various API production processes. Companies are looking to diversify their API suppliers and manufacturers to different locations instead of outsourcing it to just one manufacturer. For instance, in November 2022, Novo Nordisk spent USD 747 million for expanding its API manufacturing facility in Denmark, in November 2022, GE Healthcare invested USD 80 million for expanding its API manufacturing site in Norway. Companies that have been outsourcing API manufacturing to China to reduce costs are now aiming toward switching to other countries and are looking for backward integration. This is creating growth opportunities for other leading API-producing countries, such as India, to increase market shares in the changing market scenario.

 

Innovative Active Pharmaceutical Ingredients market dominated the market with a revenue share of 53.5% in 2021. Favorable regulations for R&D facilities and increase in funding are key factors driving the innovative Active Pharmaceutical Ingredients market. Owing to extensive research in this field, many novel innovative products are now in pipeline and are expected to be launched over the forecast period. New entrants in this segment are expected to drive the market. An example of a market player engaged in extensive R&D is Lonza, with more than 575 clinical development programs in 2018. Oncology is a leading domain for high-potency innovative API products due to need for low dosage and fewer adverse effects. Thus, highest percentage of HPAPIs is used in anticancer drugs. These APIs have also found application in hormonal imbalance, cardiovascular, musculoskeletal, and CNS drugs as well as in treatment of glaucoma. 

 

Order your copy of Free Sample of “Active Pharmaceutical Ingredients and High Potency API Industry Data Book - Active Pharmaceutical Ingredients and High Potency Active Pharmaceutical Ingredients Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

 

High Potency Active Pharmaceutical Ingredients Market Growth & Trends

 

The global high potency API market was valued at USD 23.60 billion in 2021 and is anticipated to witness growth at a rate of 6.2% over the forecast period. HPAPIs are attracting generic manufacturers’ attention due to patent expiry of blockbuster drugs. Moreover, CDMOs are constantly coming up with lower Occupational Exposure Limits (OELs) for intermediates and materials, which ensures employee safety.

 

For addressing the unmet medical needs, companies are collaborating to develop novel High Potency Active Pharmaceutical Ingredients (HPAPIs). This allows firms to use their resources to aid the development of products and enhance their supply chain. For instance, in January 2022, Lonza, BioGeneration Ventures (BGV), and Forbion announced the extension of their collaboration to include development & production of small molecules (biologics). Lonza will provide customized services to BGV and Forbion’s large molecule biologic portfolio.

 

Captive high potencyAPI manufacturing market segment is anticipated to hold high revenue share. Outsourced market segment is driven by factors such as rising demand for biopharmaceuticals and growing cost of manufacturing these molecules in-house. Moreover, dual sourcing is becoming a key strategy and increasingly being adopted by these companies. HPAPI molecules are manufactured by some pharmaceutical companies at in-house manufacturing facilities. Pharmaceutical companies invest heavily to develop in-house capabilities and specialized requirements for toxicity containment. According to Japan Pharmaceutical Manufacturers Association, Japanese pharmaceutical companies have continuously increased their investments in R&D for discovery and development of novel drugs every year. These investments represent more than 17% of total net sales. These companies have also launched their own research funds to collaborate with outside researchers to develop new drugs. For example, a3 (a-cube) and TaNeDS launched by Astellas Pharma and Daiichi Sankyo, respectively.

 

Competitive Landscape

 

Key players operating in the Active Pharmaceutical Ingredients and High Potency API Industry are –

• Novo Nordisk
• Merck KGaA
• Novartis AG
• Aurobindo Pharma
• Piramal Pharma
• Teva Pharmaceutical Industries Ltd.
• AbbVie, Inc.
• BASF SE
• Boehringer Ingelheim International GmbH
• CordenPharma
• Merck & Co., Inc.
• Dr. Reddy’s Laboratories Ltd.
• Cipla, Inc.
• Bristol-Myers Squibb Company
• Sun Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer, Inc.
• Viatris Inc.
• Albemarle Corporation
• Aurobindo Pharma

Life Science Microscopes Industry Growth Trends and Key Players

 

 

Global life science microscopes Industry data book is a collection of market sizing information & forecasts, regulatory data, reimbursement structure, competitive benchmarking analyses, macro-environmental analyses, and regulatory & technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.

The global life science microscopes industry generated over USD 3.35 billion in 2021 and is expected to grow at a CAGR of 8.9% over the forecast period. 

 

Surgical Microscopes Market Growth & Trends

 

The global surgical microscopes market was valued at USD 1.10 billion in 2021 and is anticipated to witness growth at a rate of 11.37% over the forecast period. Complex minimally invasive neurosurgery and ENT procedures demand more precision from the surgeons performing the operations. With the advent of surgical microscopes, it became easier for surgeons to perform such procedures more accurately in less time. In addition, the introduction of technologically advanced products is driving the demand for surgical microscopes as they are more precise, offer better illumination sources, and provide options for customization and technology integration based on the complexity of the procedures. Emerging technologies such as wide-angle illumination, Red Reflex illumination, automation and augmented reality microscopy are expected to boost the demand for surgical microscopes. International players like Carl Zeiss Meditec AG and Leica Microsystems are contributing to the market by providing highly advanced, automated, and robotic surgical microscopes for more precision.

 

The surgical microscopes market is segmented based on type, applications, and end-use. Based on type it is divided into casters, wall-mounted, tabletop, and ceiling-mounted. The on-caster microscopes held a significant share in 2021 and are anticipated to grow at the highest CAGR over the forecast period. Portability and flexibility of the devices for better adjustment during surgeries and easy maintenance are some of the key factors governing this segment's growth.

In-vitro Fertilization Microscopes Market Growth & Trends

 

The in-vitro fertilization microscopes market was valued at USD 94.03 million in 2021 and is expected to reach USD 193.3 million by 2030 at a CAGR of 8.37% from 2022 to 2030. Improving the success rate of In Vitro Fertilization (IVF) procedures and the availability of financial assistance are expected to boost the market growth. Moreover, product innovations by manufacturers are increasing treatment efficiency and are expected to reduce the procedure cost.

 

The inverted microscope segment dominated the overall in vitro fertilization microscopes market in terms of revenue share in 2021 due to its compatibility with micromanipulators for use in Intracytoplasmic Sperm Injection (ICSI) procedures and comparatively high product cost. The stereo microscope held the second-largest revenue share due to innovations in time-lapse microscopy, reducing the time required for embryo assessment.

 

The end-user segment is classified into clinical and academic research. The clinical segment dominated the overall in vitro fertilization microscopes market in terms of revenue share in 2021 due to factors such as increased adoption of IVF treatment. Europe dominated the in vitro fertilization microscopes market in 2021 due to factors such as growing fertility tourism, legal reforms, and product innovation. However, Asia Pacific is expected to witness the fastest growth over the forecast period owing to key factors such as increasing awareness and availability of IVF services.

 

 

Order your copy of Free Sample of “Life Science Microscopes Industry Data Book - Surgical, In-vitro Fertilization, Super Resolution And Scanning Electron Microscopes Market Size, Share, Trends Analysis And Segment Forecasts, 2022 - 2030” Data Book, published by Grand View Research

 

Super-resolution Microscopes Market Growth & Trends

 

The global super-resolution microscopes market was valued to be USD 1.2 billion in 2021 and is expected to reach USD 2.7 billion by 2030, growing at a CAGR of 9.22% over the forecast period. Increasing demand for super-resolution microscopy in nanotechnology and its wide application in the life science industry mainly in microbiology, oncology for cancer cell proliferation, biomedical imaging, and drug discovery are the key reasons for the growth of the market. Furthermore, technological advancements in diagnostic techniques, increasing government support, and corporate funding for microscopy are a few other key factors driving the market.

 

The Life Science application segment held the largest revenue share in 2021 owing to the growth in applications of super-resolution microscopy in the life science verticals such as molecular biology, biomedical imaging, and drug discovery. However, the nanotechnology segment is expected to grow with the fastest CAGR over the forecast period. 

 

North America accounted for the largest revenue share in 2021. This can be attributed to the significant development of technology in the U.S. and the local presence of top market leaders in the country. Various initiatives and funding to support the development of advanced technology by the U.S. government are also driving market growth in North America.

 

Scanning Electron Microscopes Market Growth & Trends

 

The global life science scanning electron microscope market size was valued at USD 912.02 million in 2021 and is expected to exhibit a CAGR of 7.73% during the forecast period to reach an estimated value of USD 1.79 billion by 2030. Increasing R&D activities in the field of nanotechnology & life sciences, and product innovations are some of the key factors driving the market growth. However, the high cost of scanning electron microscopes may hamper the growth of the market.

 

Based on end users, the market is segmented into material science, nanotechnology, life science, semiconductors, and other applications. In 2021, life science dominated the market due to the availability of several products with special applications in the field of life science. However, the nanotechnology segment is expected to grow at the fastest rate during the forecast period. This can be attributed to the expected launch of technologically advanced products due to growing investments by several major players and the rising adoption of such products in emerging countries.

 

Go through the table of content of Life Science Microscopes Industry Data Book to get a better understanding of the Coverage & Scope of the study.

 

Competitive Landscape

 

Key players operating in the Life Science Microscopes Industry are –

• Carl Zeiss Meditec AG
• Leica Microsystems
• Olympus Corporation
• Nikon Corporation
• Applied Precision (GE Healthcare)
• Haag-Streit Surgical GmbH
• Synaptive Medical
• Alcon, Inc. (Novartis)
• Topcon Corporation
• ARI Medical Technology Co., Ltd.
• Takagi Seiko Co., Ltd.
• Seiler Instrument Inc.
• Chammed Co. Ltd

Veterinary Imaging Instrument Industry: Advancing Technology From Fuzzy Scans To Precise Pictures

 

 

Global Veterinary Imaging Instrument industry data book is a collection of market sizing information & forecasts, regulatory data, competitive benchmarking analyses, macro-environmental analyses, and technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.

 

The global Veterinary Imaging Instrument Market size for the veterinary imaging instrument was estimated at USD 1.44 Billion in 2021 and is anticipated to increase at a CAGR of 5.7% from 2022 to 2030.

 

Veterinary X-Ray Market Analysis And Forecast

The global veterinary X-Ray market generated over USD 546.9 million in 2021 and is expected to grow at a CAGR of 4.0% over the forecast period. The market is driven by technological advancements in animal healthcare, which include effective assimilation of radiology information systems and teleradiology. Rising adoption in orthopedics and focus on innovation in animal health is anticipated to fuel demand.

 

An X-ray is a typical option for imaging to diagnose problems such as cough, trauma, fever, and troubled breathing among animals. Veterinarians use radiographs to examine pneumonia, cancer, heart problems, and other disease conditions. X-rays are the oldest but most frequently used imaging modality. Key players operating in this market are Sound; IDEXX Laboratories, Inc.; FUJIFILM Holdings America Corporation; and Carestream Health.

 

Veterinary Ultrasound Market Analysis And Forecast

The global veterinary ultrasound market was valued at USD 326.7 million in 2021 and is anticipated to witness growth at a rate of 6.8% over the forecast period. Ultrasonography is the second most used veterinary imaging diagnosis. It uses ultrasound waves of 1.5 MHz to 15 MHz frequency on the body parts and creates images based on the echo pattern received from tissues. Since ultrasound equipment is non-radiographic, it is cheaper than other imaging modalities, such as CT & MRI, and easily portable. Wide applicability, ease of usage and cost-effectiveness are key attributes expected to drive the growth of this market in the near future too.

 

Based on type, the market is segmented into 2-D ultrasound imaging, 3-D/4-D ultrasound imaging, and Doppler imaging. The 2-D ultrasound imaging segment accounted for the maximum revenue share of around 39% in 2021. The market growth is attributed to the widespread popularity of such devices in pregnancy detection as well as disease diagnosis. Furthermore, less cost as compared to other types of ultrasounds is also expected to boost the market growth.

 

Based on scanner type, the market is segmented into cart-based ultrasound scanners and handheld scanners. The cart-based ultrasound scanners segment accounted for the maximum revenue share of more than 50% in 2021. The market growth is attributed to their high adoption due to ease of use and extensive use in veterinary clinics, hospitals, and diagnostic centres,

 

Based on application, the market is classified into orthopedics, cardiology, oncology, obstetrics & gynaecology, and others. The cardiology segment accounted for the maximum revenue share of around 25.0% in 2021. The increasing prevalence of cardiac disorders in animals is expected to contribute to market growth.

 

Based on end-use, the market is segmented into veterinary hospitals & clinics and others. The hospitals & clinics segment accounted for the highest revenue share of more than 55% in 2021. The availability of a wide range of diagnostic alternatives in hospitals and clinics is anticipated to contribute to market growth. 

Order your copy of Free Sample of “Veterinary Imaging Instrument Industry Data Book - Veterinary X-Ray, Veterinary Ultrasound, Animal MRI and Animal/Veterinary CT Imaging Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

 

Animal/Veterinary MRI Market Analysis And Forecast

The Veterinary MRI market was valued at USD 198.8 million in 2021 and is expected to reach over USD 300.0 million by 2030 at a CAGR of 7.3% from 2022 to 2030. Rising usage of this modality by veterinarians in whole-body imaging due to the associated benefits such as high contrast and detailed anatomical tomographic images is expected to provide a growth platform in the coming 5 years. Moreover, rising penetration in orthopaedics, neurologic, and oncologic therapeutic applications will further boost the growth of this market.

 

MRI in ophthalmology is highly investigated in canine fibrosarcoma and feline melanoma cases. It is now widely applied in clinical areas of nasal neoplasm, musculoskeletal diseases, shoulder diseases, elbow dysplasia, ligament injuries, and orbital & eye diseases. In addition, the application of MRI in large animal research is significantly growing. Since MRI does not use ionizing radiation, it is safe in general for pregnant animals majorly during the third or second trimester.

 

Animal/Veterinary CT Imaging Market Analysis And Forecast

The global super-resolution microscopes market was valued at USD 161.5 million in 2021 and is expected to grow at a CAGR of 6.7% over the forecast period. The rise in the companion animal population coupled with the growing adoption of pet insurance is anticipated to boost the market growth. Furthermore, an increasing number of veterinary practitioners and technological advancements in the sector are expected to fuel animal/veterinary CT imaging market growth.

 

CT has been widely explored since its first veterinary application for investigating the central nervous system in dogs and cats. In most cases, CT provides valuable images that are not precise in ultrasound or other radiography procedures. CT scans can be used in different species of animals to diagnose lesions, sinuses, jaw & dental arcade, retrobulbar region, skull, joints, and appendicular skeleton. Moreover, several bone diseases are investigated using CT scans as they can image bone curvature, angles, architecture, and thickness.

 

The North American region includes the U.S. and Canada, and it dominated the global market with the highest share of over 45.0% in 2021. This can be attributed to high healthcare costs and rise in the prevalence of obesity among the pet population. Furthermore, a surge in pet insurance claims is anticipated with the growing concern about pets among pet owners. For instance, it was estimated that in the U.S. pet adoption rate was around 2.48% in 2021 with about 4.0 million total pets. 

 

Go through the table of content of Veterinary Imaging Instrument Industry Data Book to get a better understanding of the Coverage & Scope of the study.

Competitive Landscape

Key players operating in the Veterinary Imaging Instrument Industry are –

• IDEXX Laboratories, Inc.
• Canon Medical Systems Corporation
• FUJIFILM Holdings America Corporation
• Samsung
• Heska Corporation
• Butterfly Network, Inc.
• Carestream Health
• Midmark Corporation
• ESAOTE SPA
• SOUND